Hematopoietic progenitor cells (HPCs) are the stem cells primarily responsible for the formation of blood and immune cells and are indispensable for maintaining blood homeostasis and defending the body against infections. HPCs originate from multipotent hematopoietic stem cells (HSCs) and are found in specialized niches within the bone marrow, as well as in smaller amounts in other tissues, such as the liver and spleen. The bone marrow contains within it specialized niches that provide physical support and regulatory signals to HPCs. These niches consist of various cell types, extracellular matrix components, and soluble factors that help maintain HPCs in their undifferentiated, self-renewing state. Cytokines and growth factors in the bone marrow microenvironment play a pivotal role in regulating HPC self-renewal. Key cytokines include stem cell factor (SCF), thrombopoietin (TPO), and interleukin-6 (IL-6) which stimulate HPC proliferation whilst maintaining their stemness. HPCs possess the capacity to differentiate into various blood cell lineages, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes). This multipotency is essential for replenishing the body's blood cell populations and maintaining hematopoietic function. Like HSCs, HPCs have a degree of self-renewal capacity, allowing them to divide and produce identical daughter cells to maintain a pool of progenitor cells. This ensures a continuous source of blood cells throughout an individual's life. HPCs express specific cell surface markers, such as CD34 and CD133, which are often used for their identification and isolation. These markers help distinguish them from more differentiated blood cells. HPCs are committed to hematopoietic lineages, meaning they are primed to differentiate into specific types of blood cells. Their differentiation pathways are regulated by various cytokines, growth factors, and signalling molecules. HPCs exist in a hierarchical manner, with different levels of commitment to specific blood cell lineages. Common myeloid progenitors (CMPs) give rise to various myeloid cells (e.g., granulocytes, monocytes), whilst common lymphoid progenitors (CLPs) generate lymphoid cells (e.g., T cells, B cells, natural killer cells). The number and type of HPCs produced can adapt to the body's needs, responding to factors such as infection, blood loss, or stress. This ability ensures that the hematopoietic system can quickly mobilize resources when necessary. HPCs can be mobilized from the bone marrow into the bloodstream in response to signals such as granulocyte-colony stimulating factor (G-CSF). They can also home back to the bone marrow when needed, ensuring a balance within the hematopoietic system. HPC transplantation, often referred to as bone marrow transplantation, is a well-established treatment for various blood disorders and cancers. HPCs from a compatible donor can be transplanted to replace damaged or dysfunctional hematopoietic systems. Dysregulation or mutations in HPCs can lead to various blood cell disorders, including leukaemia, anaemia, and immune deficiencies. We offer a wide product range of research tools for investigating hematopoietic progenitors, including CD45 antibodies, CD4 antibodies, CD31 antibodies, ICAM1 ELISA Kits, and SCF ELISA Kits. Explore our full hematopoietic progenitors product range below and discover more, for less. Alternatively, you can explore our Lymphoid, Myeloid, and Hematopoietic Stem Cells product ranges.